What is the clinical evidence from this study?

Population: Cardiac remodeling. Intervention: Icariside II (ICA II) vs. Vehicle. Primary outcome: Cardiac remodeling (hypertrophy and fibrosis) and cardiac dysfunction.

What does this research mean for the field?

Icariside II attenuates systolic and diastolic cardiac dysfunction and protects against cardiac hypertrophy and fibrosis via activation of the AMPKα/mTORC pathway. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 1, 2018Journal of Pharmacological SciencesOpen Access

Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 in vivo and in vitro

View Full Paper

Ask AI

Bookmark

Key result

Icariside II protects mouse hearts from dysfunction and remodeling via the AMPKα/mTORC pathway.

Why the study?

Does Icariside II attenuate cardiac remodeling and hypertrophy in preclinical models?

Structured PICO

Does Icariside II attenuate cardiac remodeling and hypertrophy in preclinical models?

Population

Mice subjected to aorta banding or sham surgery and neonatal rat cardiomyocytes were used to study the effects of Icariside II on cardiac remodeling over 6 weeks.

Intervention

Icariside II (ICA II) for 6 weeks (in vivo) and in vitro

Comparator

Vehicle (veh) for in vivo; resveratrol and AICAR for in vitro

Outcome

Cardiac remodeling (hypertrophy and fibrosis) and cardiac dysfunctionsurrogate

Icariside II attenuates cardiac remodeling and hypertrophy via the AMPKα/mTORC pathway in preclinical models, suggesting potential as a therapeutic candidate.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating in mice; leaves open translation to human cardiac remodeling.

Cite This Study

Liu et al. (2018) studied Cardiac remodeling. Icariside II (ICA II) vs. Vehicle was evaluated on Cardiac remodeling (hypertrophy and fibrosis) and cardiac dysfunction. Icariside II attenuated systolic and diastolic cardiac dysfunction and protected mouse hearts from hypertrophy and fibrosis by regulating the AMPKα/mTORC pathway.

synapsesocial.com/papers/6aa56e1e246eab12a27f27d1 https://doi.org/10.1016/j.jphs.2018.08.010

View Full Paper

Ask AI

Bookmark

Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 in vivo and in vitro

Structured PICO

Discussion

Implication

Cite This Study

Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 in vivo and in vitro

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider